Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 10:28 am Sale |
2023-12-31 | 13G | Rein Therapeutics Inc. RNTX |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-236,835 (Position Closed) |
Filing History |
| 2024-02-14 10:26 am Purchase |
2023-12-31 | 13G | Annexon, Inc. ANNX |
BIOTECHNOLOGY VALUE FUND L P | 7,000,000 8.900% |
3,219,306 (+85.15%) |
Filing History |
| 2024-02-14 10:24 am Purchase |
2023-12-31 | 13G | Aravive, Inc. ARAV |
BIOTECHNOLOGY VALUE FUND L P | 8,164,510 9.990% |
2,055,452 (+33.65%) |
Filing History |
| 2024-02-14 10:22 am Purchase |
2023-12-31 | 13G | ASLAN Pharmaceuticals Limited ASLN |
BIOTECHNOLOGY VALUE FUND L P | 5,418,122 9.990% |
5,418,122 (New Position) |
Filing History |
| 2024-02-14 10:20 am Sale |
2023-12-31 | 13G | Bionomics Limited BNOX |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-14,174,157 (Position Closed) |
Filing History |
| 2024-02-14 10:18 am Purchase |
2023-12-31 | 13G | Cidara Therapeutics, Inc. CDTX |
BIOTECHNOLOGY VALUE FUND L P | 463,776 9.990% |
120,720 (+35.19%) |
Filing History |
| 2024-02-14 10:16 am Sale |
2023-12-31 | 13G | Cullinan Oncology, Inc. CGEM |
BIOTECHNOLOGY VALUE FUND L P | 4,393,321 9.990% |
-3,115,738 (-41.49%) |
Filing History |
| 2024-02-14 10:13 am Purchase |
2023-12-31 | 13G | Centessa Pharmaceuticals plc CNTA |
BIOTECHNOLOGY VALUE FUND L P | 8,774,570 9.000% |
1,880,225 (+27.27%) |
Filing History |
| 2024-02-14 10:11 am Sale |
2023-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-2,736,613 (Position Closed) |
Filing History |
| 2024-02-14 10:09 am Purchase |
2023-12-31 | 13G | CytomX Therapeutics, Inc. CTMX |
BIOTECHNOLOGY VALUE FUND L P | 6,702,889 9.990% |
107,088 (+1.62%) |
Filing History |
| 2024-02-14 10:08 am Purchase |
2023-12-31 | 13G | Delcath Systems, Inc. DCTH |
BIOTECHNOLOGY VALUE FUND L P | 2,338,426 9.990% |
776,912 (+49.75%) |
Filing History |
| 2024-02-14 10:06 am Purchase |
2023-12-31 | 13G | Eledon Pharmaceuticals, Inc. ELDN |
BIOTECHNOLOGY VALUE FUND L P | 4,326,710 17.900% |
2,000,000 (+85.96%) |
Filing History |
| 2024-02-14 10:01 am Purchase |
2023-12-31 | 13G | Elevation Oncology, Inc. ELEV |
BIOTECHNOLOGY VALUE FUND L P | 4,450,885 9.990% |
2,138,685 (+92.50%) |
Filing History |
| 2024-02-14 09:58 am Purchase |
2023-12-31 | 13G | 89bio, Inc. ETNB |
BIOTECHNOLOGY VALUE FUND L P | 7,568,480 7.800% |
4,047,354 (+114.94%) |
Filing History |
| 2024-02-14 09:56 am Unchanged |
2023-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
BIOTECHNOLOGY VALUE FUND L P | 4,007,413 9.400% |
0 (Unchanged) |
Filing History |
| 2024-02-14 09:54 am Purchase |
2023-12-31 | 13G | GH Research PLC GHRS |
BIOTECHNOLOGY VALUE FUND L P | 10,400,158 19.990% |
1,125,000 (+12.13%) |
Filing History |
| 2024-02-14 09:52 am Unchanged |
2023-12-31 | 13G | Galmed Pharmaceuticals Ltd. GLMD |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2024-02-14 09:50 am Purchase |
2023-12-31 | 13G | IDEAYA Biosciences, Inc. IDYA |
BIOTECHNOLOGY VALUE FUND L P | 3,479,043 5.300% |
1,023,954 (+41.71%) |
Filing History |
| 2024-02-14 09:47 am Purchase |
2023-12-31 | 13G | Ikena Oncology, Inc. IKNA |
BIOTECHNOLOGY VALUE FUND L P | 4,769,164 9.900% |
2,266,093 (+90.53%) |
Filing History |
| 2024-02-14 09:45 am Sale |
2023-12-31 | 13G | iTeos Therapeutics, Inc. ITOS |
BIOTECHNOLOGY VALUE FUND L P | 1,259,476 3.500% |
-551,359 (-30.45%) |
Filing History |